Comparative Pharmacology
Head-to-head clinical analysis: HISTAFED versus TAVIST 1.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HISTAFED versus TAVIST 1.
HISTAFED vs TAVIST-1
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
HISTAFED is a combination of pseudoephedrine, a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the nasal mucosa causing vasoconstriction, and triprolidine, a first-generation antihistamine that competes with histamine for H1-receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract, thereby preventing histamine-mediated effects.
TAVIST-1 (clemastine fumarate) is a first-generation antihistamine that acts as a competitive antagonist at histamine H1 receptors, thereby preventing histamine-mediated effects such as vasodilation, increased capillary permeability, and bronchoconstriction. It also exhibits anticholinergic and sedative properties.
60 mg orally every 4 to 6 hours as needed; maximum 360 mg per day.
1.34 mg orally twice daily; maximum 8.04 mg/day.
None Documented
None Documented
3-4 hours for pseudoephedrine component; shorter in children (2-3 h), prolonged in renal impairment
Terminal half-life 12–15 hours; clinical dosing interval every 12 hours.
Renal (approximately 65% as unchanged drug and metabolites), biliary/fecal (35%)
Primarily renal: ~60% unchanged; biliary/fecal: ~30% as metabolites; minor via feces.
Category C
Category C
Antihistamine/Decongestant Combination
Antihistamine